The GRPR antagonist [177Lu]Lu-RM2 was studied for the treatment of patients with metastatic castration-resistant prostate cancer by delivering at least one therapy cycle of the GRPR-targeting radioligand [23]. This evidence concerns the gene GRPR and Familial prostate cancer.